Description: Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers, as well as ovarian and other solid tumors; LYL845, an IV administered autologous TIL therapy for multiple solid tumors; and NY-ESO-1, a T cell product candidate for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
Home Page: www.lyell.com
LYEL Technical Analysis
201 Haskins Way
South San Francisco,
CA
94080
United States
Phone:
650 695 0677
Officers
| Name | Title |
|---|---|
| Dr. Richard D. Klausner M.D. | Founder & Exec. Chairman |
| Ms. Elizabeth Homans | CEO & Director |
| Mr. Charles W. Newton | Chief Financial Officer |
| Mr. Stephen J. Hill | Chief Operating Officer |
| Prof. Stanley R. Riddell M.D. | Founder & Scientific Advisor |
| Dr. Crystal L. Mackall M.D. | Founder & Scientific Advisor |
| Nellie Dillery | Director of Accounting |
| Mr. Richard Goold Ph.D. | Chief Information Officer |
| Dr. Gary Lee Ph.D. | Chief Scientific Officer |
| Ellen Rose | VP of Communications & Investor Relations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 2.1769 |
| Price-to-Book MRQ: | 1.0657 |
| Price-to-Sales TTM: | 20.9052 |
| IPO Date: | 2021-06-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 219 |